We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
76
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.76M 0.14%
165,515
+39,616
+31% +$793K
SGYPW
77
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$2.69M 0.13%
9,727
+6,942
+249% +$6.66K
MNTA
78
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.59M 0.13%
280,225
+130,195
+87% +$1.4M
DERM
79
DELISTED
Dermira, Inc.
DERM
$2.54M 0.13%
+122,600
New +$3.01M
ASXC
80
CALL
DELISTED
Asensus Surgical, Inc.
ASXC
$2.51M 0.13%
455
-736
-62% -$31.5K
DVAX
81
CALL
DELISTED
Dynavax Technologies
DVAX
$2.5M 0.13%
1,300
-607
-32% -$12.3K
ANAC
82
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$2.38M 0.12%
44,439
+24,439
+122% +$1.8M
ZGNX
83
DELISTED
Zogenix, Inc.
ZGNX
$2.35M 0.12%
+254,424
New +$2.55M
LJPC
84
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.35M 0.12%
112,184
+47,026
+72% +$839K
SRPT icon
85
CALL
Sarepta Therapeutics
SRPT
$1.66B
$2.33M 0.12%
1,193
-1,669
-58% -$29.2K
KYNB
86
Kyntra Bio
KYNB
$28.5M
$2.32M 0.12%
+4,364
New +$2.17M
LUMO
87
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$2.32M 0.12%
14,162
-4,868
-26% -$987K
DBVT
88
DBV Technologies
DBVT
$807M
$2.28M 0.11%
7,000
+2,341
+50% +$657K
GBT
89
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.17M 0.11%
137,000
-205,857
-60% -$3.66M
ITCI
90
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.17M 0.11%
+78,000
New +$2.6M
TVTX icon
91
Travere Therapeutics
TVTX
$5.33B
$2.14M 0.11%
+156,774
New +$2.38M
ADXS
92
CALL
DELISTED
Advaxis Inc
ADXS
$2.1M 0.11%
+155
New +$17.1K
IOVA icon
93
Iovance Biotherapeutics
IOVA
$2.23B
$2.09M 0.1%
412,246
+142,246
+53% +$778K
RDUS
94
DELISTED
Radius Health, Inc.
RDUS
$2.04M 0.1%
+65,000
New +$2.25M
SRNE
95
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$2.04M 0.1%
379,800
+79,800
+27% +$464K
FOLD
96
CALL
DELISTED
Amicus Therapeutics
FOLD
$2.03M 0.1%
2,405
+668
+38% +$4.73K
OASM
97
DELISTED
Oasmia Pharmaceutical AB
OASM
$2.02M 0.1%
477,836
-185,302
-28% -$657K
HALO icon
98
CALL
Halozyme
HALO
$9.72B
$1.92M 0.1%
2,029
-1,985
-49% -$18.7K
AKRX
99
CALL
DELISTED
Akorn Inc
AKRX
$1.92M 0.1%
+815
New +$21.4K
RDHL
100
Redhill Biopharma
RDHL
$3.85M
$1.92M 0.1%
157
-3
-2% -$31.4K
2 3
4
5 6

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.